O
KRYS icon

OrbiMed’s Krystal Biotech KRYS Stock Holding History

OrbiMed’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9M Buy
83,200
+14,100
+20% +$4.21M 0.57% 49
2026
Q1 		$17.8M Sell
69,100
-50,700
-42% -$13.5M 0.35% 60
2025
Q4 		$29.5M Buy
119,800
+17,055
+17% +$3.59M 0.6% 49
2025
Q3 		$18.1M Buy
102,745
+93,545
+1,017% +$14M 0.43% 55
2025
Q2 		$1.26M Sell
9,200
-14,300
-61% -$2.1M 0.03% 90
2025
Q1 		$4.24M Hold
23,500
– – 0.1% 81
2024
Q4 		$3.68M Hold
23,500
– – 0.08% 92
2024
Q3 		$4.28M Sell
23,500
-6,466
-22% -$1.25M 0.08% 101
2024
Q2 		$5.5M Sell
29,966
-7,200
-19% -$1.21M 0.11% 87
2024
Q1 		$6.61M Sell
37,166
-66,534
-64% -$9.24M 0.12% 92
2023
Q4 		$12.9M Buy
+103,700
New +$11.5M 0.26% 71
2020
Q1 		– Sell
-994,808
Closed -$55.1M – 154
2019
Q4 		$55.1M Buy
994,808
+392,858
+65% +$19.3M 0.79% 41
2019
Q3 		$20.9M Sell
601,950
-40,056
-6% -$1.79M 0.4% 61
2019
Q2 		$25.9M Buy
642,006
+582,796
+984% +$19.1M 0.4% 59
2019
Q1 		$1.95M Buy
+59,210
New +$1.4M 0.03% 116

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed's KRYS Position: Q2 2026 in Review

OrbiMed increased its Krystal Biotech (KRYS) stake by 20% in Q2 2026, buying an estimated $4.21M and bringing the position to 83,200 shares worth $30.9M. The position accounts for 0.57% of the portfolio, ranked #49.

OrbiMed first reported a position in KRYS in Q1 2019 and has held it in 15 quarters since. The position peaked at $55.1M in Q4 2019. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • OrbiMed held 83,200 shares of Krystal Biotech worth $30.9M as of Q2 2026.
  • OrbiMed bought 14,100 Krystal Biotech shares in Q2 2026, an estimated $4.21M.
  • Krystal Biotech made up 0.57% of OrbiMed's portfolio in Q2 2026, its #49 holding.
  • OrbiMed first reported a position in Krystal Biotech in Q1 2019 and has held it in 15 quarters since.
  • OrbiMed's Krystal Biotech position peaked at $55.1M in Q4 2019.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.